Feminizing Hormone Therapy Prescription Patterns and Cardiovascular Risk Factors in Aging Transgender Individuals in Australia

CONTEXT: The safety and efficacy of feminizing hormone therapy in aging transgender (trans) individuals is unclear. Current recommendations suggest transdermal estradiol beyond the age of 45 years, especially if cardiometabolic risk factors are present. OBJECTIVE: To evaluate feminizing hormone ther...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Front Endocrinol (Lausanne)
Asıl Yazarlar: Balcerek, Matthew I., Nolan, Brendan J., Brownhill, Adam, Wong, Peggy, Locke, Peter, Zajac, Jeffrey D., Cheung, Ada S.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Frontiers Media S.A. 2021
Konular:
Endocrinology
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8313995/
https://ncbi.nlm.nih.gov/pubmed/34326812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2021.667403
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller